Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05415072 : A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

12+Age Over 12

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Head and neck,SkinMelanoma (Ocular),Melanoma (Skin)

Trial Overview Read MoreRead more

This phase I/II study is seeking to determine the best dose level, safety and effect, of a new cancer drug (DYP688) in people with metastatic ocular (uveal) melanoma.
 

This trial is treating patients with metastatic uveal (ocular) melanoma, and other melanomas harbouring GNAQ/11 mutations.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

Commercial Sponsor

Novartis Pharmaceuticals

Summary

There will be two parts to this study: a phase I, dose escalation part followed by a phase II part. Dose escalation will be conducted in people with metastatic uveal melanoma (MUM) and other melanomas with GNAQ/11 mutations. Once the maximum tolerated dose (MTD) and/or recommended doses (RD) is determined in the dose escalation part, the study may continue with a phase II part. The phase II part will be conducted in two groups of participants with MUM, a group that has received prior treatment with tebentafusp, and a group that has not received prior treatment with tebentafusp. In addition to MUM, a third group of participants with a non-uveal GNAQ/11 mutant melanomas may also be explored. This cohort may be opened based on emerging data from teh dose escalation part of the study.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Monc C Co-Team Leads
PCCTU.MoncC@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next